VACCINATION AGAINST SEASONAL INFLUENZA AND PNEUMONIA IMPROVES CLINICAL OUTCOME IN MULTIPLE MYELOMA PATIENTS RECEIVING CONTINUOUS TREATMENT WITH LENALIDOMIDE: A REAL-LIFE SURVEY

EHA Library, Anna Bulla, 324727

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN EAST ASIAN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: IKEMA SUBGROUP ANALYSIS

EHA Library, Kihyun Kim, 324729

TUMOR CHARACTERISTICS OF DISEASE PROGRESSION AFTER BCMA-CART TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA WITH EXTRAMEDULLARY LESIONS

EHA Library, Yuelu Guo, 324730

ASSESSMENT OF TREATMENT RESPONSE BY MASS SPECTROMETRY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS FROM THE GEM2012MENOS65 CLINICAL TRIAL: COMPARISON WITH STANDARD SPEP/IFE

EHA Library, Noemi Puig, 324735

EARLY MORTALITY AMONG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE NETHERLANDS: A POPULATION-BASED STUDY

EHA Library, Mirian Brink, 324743

IMPACT OF T(11;14) ACCORDING TO INDUCTION REGIMEN IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS: LONG TERM FOLLOW-UP OF GEM05MENOS65 PETHEMA/GEM STUDY

EHA Library, David Moreno, 324744

PHASE 3 STUDY OF DARATUMUMAB, BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN ASIAN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): OCTANS

EHA Library, Jian Hou, 324747

OVERALL, COMPLETE, AND STRINGENT COMPLETE RESPONSE RATES AND MINIMAL RESIDUAL DISEASE AS POTENTIAL SURROGATES FOR PROGRESSION-FREE SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Patrick Daniele, 324748

GAIN IN CHROMOSOME 1 SIGNIFICANTLY IMPACTS SURVIVAL IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

EHA Library, Isabel Mesquita, 324755

OVERALL AND COMPLETE RESPONSE RATES AS POTENTIAL SURROGATES FOR OVERALL SURVIVAL IN RELAPSED REFRACTORY MULTIPLE MYELOMA

EHA Library, Patrick Daniele, 324756

RAPID IMPLEMENTATION NATIONWIDE OF NEW TREATMENTS IN MULTIPLE MYELOMA, EXPERIENCE FROM MORE THAN 10.000 PATIENTS IN THE DANISH AND SWEDISH NATIONAL REGISTRIES.

EHA Library, Cecilie Hveding Blimark, 324758

PREDICTIVE FACTORS RELATED TO DISEASE PROGRESSION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE IN A SINGLE CENTER DURING 9 YEARS

EHA Library, Junling Zhuang, 324760

MULTIPLE MYELOMA TREATMENT PATTERNS AND OUTCOMES IN THE PUBLIC AND PRIVATE HEALTHCARE SYSTEMS IN BRAZIL: ONE COUNTRY, TWO WORLDS - MMYBRAVE STUDY

EHA Library, Vania Hungria, 324762

THE USE OF NON-CRYOPRESERVED AND CRYOPRESERVED HEMATOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION IN MULTIPLE MYELOMA.

EHA Library, Andrei Garifullin, 324763

MAINTAINING DELIVERY OF HIGH QUALITY SPECIALIZED CARE IN PATIENTS WITH MYELOMA DURING THE COVID-19 PANDEMIC: COMPARING 2019 TO 2020

EHA Library, Efstathios Kastritis, 324764

IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN ROUTINE PRACTICE: EXTENDED SUBGROUP ANALYSIS

EHA Library, Jiri Minarik, 324765

RESPONSE-ADJUSTED ISS SCORE IN TRANSPLANT INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA: DOES IT MATTER?

EHA Library, Aleksandra Sretenovic, 324766

CHARACTERISTICS AND OUTCOME OF TRANSPLANT INELIGIBLE MYELOMA PATIENTS ACHIEVING SUSTAINED PARTIAL RESPONSE VS. THOSE EXHIBITING COMPLETE REMISSION AFTER 1ST LINE THERAPY: SINGLE CENTER REAL-WORLD DATA

EHA Library, Theodora Triantafyllou, 324767

ASSESSING TIME TO DETERIORATION IN HRQOL IN PATIENTS WITH MULTIPLE MYELOMA USING VENETOCLAX IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE COMPARED WITH PATIENTS USING BORTEZOMIB AND DEXAMETHASONE

EHA Library, Philippe Moreau, 324769

DISCREPANCIES IN ETHNIC DIVERSITY OF PATIENTS ENROLLED INTO UK MULTIPLE MYELOMA CLINICAL TRIALS

EHA Library, Samir Asher, 324770

CILTACABTAGENE AUTOLEUCEL VERSUS SELINEXOR + DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH ≥3 LINES OF PRIOR THERAPY: A MATCHING ADJUSTED INDIRECT COMPARISON

EHA Library, Thomas Martin, 324772

IXAZOMIB VERSUS LENALIDOMIDE OR IXAZOMIB AND LENALIDOMIDE COMBINATION AS MAINTENANCE REGIMEN FOR PATIENTS WITH MULTIPLE MYELOMA: INTERIM ANALYSIS OF A MULTI-CENTER PROSPECTIVE STUDY IN CHINA

EHA Library, Junling Zhuang, 324773

QUANTIFYING THE BURDEN OF ILLNESS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA, AND THEIR CAREGIVERS, IN THE FIRST YEAR AFTER DIAGNOSIS

EHA Library, Brett Gardiner, 324775

INTERMITTENT TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: RESULTS OF A PHASE II TRIAL EVADING AUTOLOUGOS STEM CELL TRANSPLANT (ASCT)

EHA Library, Maher Salamoon, 324778

TAMOXIFEN CAN REDUCE MITOCHONDRIAL RESPIRATION, ONCOGENIC JAK-STAT SIGNALING AND MUTANT ALLELE BURDEN IN A SUBSET OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – RESULTS OF THE TAMARIN PHASE II STUDY

EHA Library, Zijian Fang, 324781

INVESTIGATION OF FEASIBILITY AND EFFICACY OF AN ANTI-INFLAMMATORY ANTI-IL-6 TREATMENT IN THE JAK2-V617F MOUSE MODEL

EHA Library, Conny Baldauf, 324782

CDK4/CDK6-INHIBITION AS A POTENT APPROACH TO AUGMENT ANTI-NEOPLASTIC EFFECTS OF MIDOSTAURIN, AVAPRITINIB AND NINTEDANIB IN KIT D816V+ NEOPLASTIC MAST CELLS

EHA Library, Mathias Schneeweiss-Gleixner, 324788

AVAPRITINIB AND NINTEDANIB INHIBIT GROWTH AND SURVIVAL OF KIT D816V+ HUMAN MAST CELLS

EHA Library, Susanne Gamperl, 324793

RELATIONSHIP BETWEEN MOLECULAR PROFILE AND PLATELET FUNCTION AND THROMBIN GENERATION IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA

EHA Library, Mercedes Gasior Kabat, 324795

A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ADVANCED MYELOFIBROSIS

EHA Library, Harinder Gill, 324797

NAVITOCLAX AND RUXOLITINIB FOR PATIENTS WITH MYELOFIBROSIS AND JAK INHIBITOR EXPERIENCE: RESPONSE DURATION IN PHASE 2 STUDY

EHA Library, Claire Harrison, 324801

BET INHIBITOR PELABRESIB DECREASES INFLAMMATORY CYTOKINES, IMPROVES BONE MARROW FIBROSIS AND FUNCTION, AND DEMONSTRATES CLINICAL RESPONSE IRRESPECTIVE OF MUTATION STATUS IN MYELOFIBROSIS PATIENTS

EHA Library, Patricia Keller, 324803

GENOMIC PROFILING OF MYELOPROLIFERATIVE NEOPLASMS WITH SPLANCHNIC VEIN THROMBOSIS

EHA Library, Marta Garrote Ordeig, 324807

SAFETY AND EFFICACY OF MEPOLIZUMAB IN HYPEREOSINOPHILIC SYNDROME: AN OPEN-LABEL EXTENSION STUDY

EHA Library, Florence Roufosse, 324810

IMPACT OF BONE MARROW FIBROSIS GRADE ON RESPONSE AND OUTCOME IN PATIENTS WITH PRIMARY MYELOFIBROSIS TREATED WITH RUXOLITINIB: A POST-HOC ANALYSIS OF THE JUMP STUDY

EHA Library, Francesca Palandri, 324815

WHEN MYELOPROLIFERATIVE NEOPLASMS MEET COVID-19: INFLAMMATION, ENDOTHELIOPATHY AND COAGULOPATHY

EHA Library, Rossella Cacciola, 324817

FIRST REAL-LIFE RESULTS ON PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH MIDOSTAURIN IN FRANCE

EHA Library, Julien Rossignol, 324818

ACQUIRED VON WILLEBRAND SYNDROME IN MYELOPROLIFERATIVE NEOPLASMS WITH EXTREME THROMBOCYTOSIS

EHA Library, Chiara Trotti, 324820

INFECTIOUS AND THROMBOTIC COMPLICATIONS AND THEIR PROGNOSTIC IMPACT IN PATIENTS WITH CONCOMITANT MYELOID AND LYMPHOID NEOPLASMS. A SINGLE-CENTER COHORT STUDY

EHA Library, Cristina Bucelli, 324821

MYELOPROLIFERATIVE NEOPLASMS IN PEDIATRICS AND YOUNG ADULTS: GENOMIC FEATURES, CLINICAL OUTCOMES, PROGRESSION AND OVERALL SURVIVAL

EHA Library, Zoey Harris, 324822

IMPACT OF EARLY RESPONSE ON OUTCOMES IN AL AMYLOIDOSIS FOLLOWING TREATMENT WITH FRONTLINE BORTEZOMIB

EHA Library, Sriram Ravichandran, 324723

RELATIONSHIP BETWEEN CORNEAL EXAM FINDINGS, BEST-CORRECTED VISUAL ACUITY (BCVA), AND OCULAR SYMPTOMS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING BELANTAMAB MAFODOTIN

EHA Library, evangelos Terpos, 324724

SELINEXOR CONTAINING REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH ANTI-CD38 MONOCLONAL ANTIBODIES

EHA Library, Cristina Gasparetto, 324725

INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE EVENTS IN THE PHASE 2 CARTITUDE-2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Hermann Einsele, 324726

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN MULTIPLE MYELOMA PATIENTS REFRACTORY TO LENALIDOMIDE

EHA Library, Xavier Leleu, 324728

ORAL SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (XPD) AT RECOMMENDED PHASE 2 DOSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

EHA Library, Darrell White, 324731

IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: UPDATED KARMMA RESULTS

EHA Library, Albert Oriol, 324732

ANALYSIS OF A PHASE 2 MINIMAL RESIDUAL DISEASE (MRD)-ADAPTIVE TRIAL OF ELOTUZUMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ELO-KRD) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)

EHA Library, Benjamin A Derman, 324733

REAL-WORLD DATA ON PATIENT CHARACTERISTICS AND TREATMENT PATTERNS FOR 3000 PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS IN EUROPE BETWEEN 2011 AND 2018: A RETROSPECTIVE STUDY BY THE EUROPEAN MYELOMA NETWORK

EHA Library, Efstathios Kastritis, 324734

A META-ANALYSIS OF EFFICACY OF POMALIDOMIDE-BASED REGIMENS FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE EXPOSURE

EHA Library, Faith Davies, 324736

SAFETY AND EFFICACY OF DARATUMUMAB WITH IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH ONE PRIOR LENALIDOMIDE-BASED REGIMEN: THE DARIA STUDY

EHA Library, evangelos Terpos, 324737

EARLY INTENSIVE CONSOLIDATION WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

EHA Library, Samiksha Gupta, 324738

RESULTS ON EFFICACY AND SAFETY OF DARATUMUMAB WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: THE DARE STUDY

EHA Library, Efstathios Kastritis, 324739

SAFETY AND TOLERABILITY OF CAEL-101 IN COMBINATION WITH CYCLOPHOSPHAMIDE-BORTEZOMIB-DEXAMETHASONE AND DARATUMUMAB IN PATIENTS WITH AL AMYLOIDOISIS

EHA Library, Jason Valent, 324740

SAFETY AND TOLERABILITY OF CAEL-101 IN PATIENTS WITH AL AMYLOIDOSIS IN A PHASE 2 STUDY FOR A MEDIAN OF 38 WEEKS

EHA Library, Jason Valent, 324741

POMALIDOMIDE, DEXAMETHASONE, AND DARATUMUMAB IN RELAPSED REFRACTORY MULTIPLE MYELOMA (MM-014 PHASE 2 TRIAL): A SUBANALYSIS OF PATIENTS PREVIOUSLY TREATED WITH LENALIDOMIDE AND A PROTEASOME INHIBITOR

EHA Library, Nizar J Bahlis, 324742

RISK OF MULTIPLE MYELOMA AND OTHER MALIGNANCIES AMONG FIRST- AND SECOND-DEGREE RELATIVES; A POPULATION BASED STUDY OF10035 PATIENTS IN NORWAY WITH MULTIPLE MYELOMA

EHA Library, Øystein Langseth, 324745

BELANTAMAB MAFODOTIN TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY MYELOMA VIA GSK EXPANDED ACCESS PROGRAM: REAL-WORLD DATA

EHA Library, Tamir Shragai, 324746

CHARACTERIZATION OF OCULAR ADVERSE EVENTS IN PATIENTS RECEIVING BELANTAMAB MAFADOTIN FOR ≥12 MONTHS: POST-HOC ANALYSIS OF DREAMM-2 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Sagar Lonial, 324749

HEALTH-RELATED QUALITY OF LIFE IN UNFIT AND FRAIL NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB

EHA Library, Claudia A.M. Stege, 324750

BRIDGE (OP-107): A PHASE 2 PHARMACOKINETIC STUDY OF MELFLUFEN PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION

EHA Library, Ludek Pour, 324751

PROGNOSTIC FACTORS AND OUTCOMES OF MULTIPLE MYELOMA PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 OR UNDER DIALYSIS

EHA Library, Ji Hyun Lee, 324752

A PHASE IA STUDY OF BISTHIANOSTAT, A NOVEL PAN-HDAC INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS OF CH-020PI STUDY

EHA Library, Hong-Hui Huang, 324753

TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH POMALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT SUBCUTANEOUS DARATUMUMAB: PATIENT-REPORTED OUTCOMES FROM APOLLO

EHA Library, Meletios Dimopoulos, 324754

BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN HEAVILY PRETREATED MULTIPLE MYELOMA: OLD/NEW IN NOVEL AGENTS' ERA

EHA Library, Claudio Cerchione, 324757

DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN (AL) AMYLOIDOSIS: A PHASE II MULTICENTER STUDY BY THE EUROPEAN MYELOMA NETWORK

EHA Library, Efstathios Kastritis, 324759

CARFILZOMIB-CONTAINING REGIMENS FOR RELAPSED MULTIPLE MYELOMA IN A REAL-WORLD SETTING: A MULTI-INSTITUTIONAL REPORT FROM THE CANADIAN MYELOMA RESEARCH GROUP (CMRG)

EHA Library, Arleigh McCurdy, 324761

EFFICACY AND SAFETY OF DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA: A SERIES OF COCHRANE REVIEWS

EHA Library, Caroline Hirsch, 324768

DETECTION OF CIRCULATING TUMOR CELLS IN MULTIPLE MIELOMA BY FLOW CYTOMETRY AND CLINICAL SIGNIFICANCE

EHA Library, Julia Tchuxina, 324771

ASSESSMENT OF CLINICAL USE PARAMETERS ASSOCIATED WITH A SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS DARATUMUMAB ADMINISTRATION IN PATIENTS WITH MULTIPLE MYELOMA AT MAYO CLINIC

EHA Library, Scott Soefje, 324774

EVERY CLOUD HAS A SILVER LINING: EVEN AN EARLY HEMATOLOGICAL PARTIAL RESPONSE COULD IDENTIFY LONG-TERM SURVIVORS IN HIGH-RISK AL AMYLOIDOSIS PATIENTS. A SINGLE CENTER EXPERIENCE.

EHA Library, Marcello Riva, 324776

DARATUMUMAB (DARA), CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE: A QUADRUPLET INTENSIFIED TREATMENT FOR TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TE NDMM) PATIENTS

EHA Library, Edvan Crusoe, 324777

THE RETROSPECTIVE ANALYSIS OF MULTIPLE MYELOMA PATIENT SURVIVAL IN ARMENIA

EHA Library, Lusine SAHAKYAN, 324779

ANTI-TMPRSS6 RNAI THERAPY AS A NOVEL TREATMENT OPTION FOR POLYCYTHAEMIA VERA

EHA Library, Cavan Bennett, 324780

EXOSOMES IN POLYCYTHEMIA VERA: 'MINI PLATELETS' WITH ONCOGENIC AND THROMBOGENIC POTENTIAL

EHA Library, Orit Uziel, 324783

RUXOLITINIB DOWN-REGULATES SELECTIVELY-ACTIVATED CCL2/CCR2 SIGNALING AXIS IN PRIMARY MYELOFIBROSIS CELLS

EHA Library, Elena Masselli, 324784

FEDRATINIB DEMONSTRATES LIMITED SUPPRESSION OF T- AND NATURAL KILLER- (NK) CELL ACTIVITY EX VIVO COMPARED WITH RUXOLITINIB AT CLINICALLY RELEVANT DOSES

EHA Library, Aarif Ahsan, 324785

DISTINCT GENE EXPRESSION PROFILES AND MOLECULAR MARKERS IN CD34+ CELLS FROM PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Julian Baumeister, 324786

CLONAL HAEMATOPOIESIS PROMOTES ADVERSE OUTCOMES IN CHRONIC KIDNEY DISEASE

EHA Library, Nick Cross, 324787

TARGETING HDAC AS A NOVEL THERAPEUTIC APPROACH TO COUNTERACT GROWTH OF NEOPLASTIC MAST CELLS IN ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Barbara Peter, 324789

ONCOGENE-INDUCED MALADAPTIVE ACTIVATION OF TRAINED IMMUNITY IN THE PATHOGENESIS OF HUMAN INFLAMMATORY MYELOID NEOPLASM

EHA Library, Eleonora Cantoni, 324790

THE SYNTHETIC TRITERPENOID CDDO-ME BLOCKS SURVIVAL OF NEOPLASTIC MAST CELLS AND SYNERGIZES WITH KIT D816V-TARGETING DRUGS IN INDUCING GROWTH INHIBITION

EHA Library, Max V. John, 324791

GENOMIC LANDSCAPE OF NON-DRIVER MUTATIONS IN MYELOPROLIFERATIVE NEOPLASMS - THE STANFORD EXPERIENCE

EHA Library, Sohail Khurshid, 324792

CALR MUTATION CLEARANCE IN RUSSIAN PATIENTS WITH PHI-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS TREATED WITH INTERFERON-ALPHA

EHA Library, Svetlana Treglazova, 324794

MECHANISTIC ABSORPTION PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR THE MURINE DOUBLE MINUTE 2 (MDM2) INHIBITOR KRT-232: PREDICTION OF FOOD AND PROTON PUMP INHIBITOR EFFECTS

EHA Library, Jin Dong, 324796

ADD-ON PARSACLISIB (A PI3K-DELTA INHIBITOR) IN PATIENTS WITH MYELOFIBROSIS AND SUBOPTIMAL RESPONSE TO RUXOLITINIB: INTERIM ANALYSIS FROM A PHASE 2 STUDY

EHA Library, Abdulraheem Yacoub, 324798

TOWARDS A POTENTIAL OPERATIONAL CURE IN PATIENTS WITH POLYCYTHAEMIA VERA? RESULTS FROM FIVE YEARS’ ROPEGINTERFERON ALPHA-2B THERAPY IN A RANDOMIZED SETTING

EHA Library, Jean-Jacques Kiladjian, 324799

PELABRESIB (CPI-0610) IMPROVED ANEMIA ASSOCIATED WITH MYELOFIBROSIS: INTERIM RESULTS FROM MANIFEST PHASE 2 STUDY

EHA Library, Srdan Verstovsek, 324800

HIGH MOLECULAR RISK MUTATIONS ARE BIOMARKERS OF CLINICAL RESPONSE AND OUTCOME IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 324802

IMPROVED TRANSFUSION INDEPENDENCE RATES FOR MOMELOTINIB VS RUXOLITINIB IN ANEMIC JAKI NAÏVE MYELOFIBROSIS PATIENTS INDEPENDENT OF BASELINE PLATELET OR TRANSFUSION STATUS

EHA Library, Jean-Jacques Kiladjian, 324804

INTENSIVE AND NONINTENSIVE BLAST REDUCTION THERAPY IN ACCELERATED AND BLAST PHASE OF BCR-ABL NEGATIVE MPN

EHA Library, Marta Davidson, 324805

CLINICAL AND MOLECULAR FACTORS AFFECTING SURVIVAL AFTER JAK-INHIBITOR FAILURE IN MYELOFIBROSIS: LONG-TERM DATA FROM A MOLECULARLY ANNOTATED COHORT

EHA Library, James T. England, 324806

CLINICAL BENEFIT OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB IN JAK INHIBITOR TREATMENT NAÏVE MYELOFIBROSIS PATIENTS: INTERIM EFFICACY SUBGROUP ANALYSIS FROM ARM 3 OF MANIFEST PH2 STUDY

EHA Library, Marina Kremyanskaya, 324808

A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)

EHA Library, David Ross, 324809

INCREASED RISK OF PRETERM BIRTH IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – A POPULATION BASED COHORT STUDY FROM SWEDEN

EHA Library, Anna Ravn Landtblom, 324811

LONG-TERM FOLLOW-UP OF RECOVERED MPN PATIENTS WITH COVID-19

EHA Library, Tiziano Barbui, 324812

AN EPIDEMIOLOGICAL STUDY OF THE CARDIOVASCULAR HEALTH AND THROMBOTIC RISK PROFILES OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS IN PRIMARY CARE ACROSS THE UNITED KINGDOM

EHA Library, Frederick Chen, 324813

ANALYSIS OF THROMBOTIC AND BLEEDING COMPLICATIONS IN 1381 ESSENTIAL THROMBOCYTHEMIA PATIENTS ASSESSED BY R-IPSET THROMBOSIS RISK SCORE: A MULTICENTER RETROSPECTIVE STUDY

EHA Library, Marta Sobas, 324814

CLINICAL AND MOLECULAR FACTORS ASSOCIATED WITH THROMBOSIS IN MYELOFIBROSIS

EHA Library, Aniket Bankar, 324816

OVERALL AND CAUSE SPECIFIC CHANGES IN MORTALITY OF PATIENTS WITH MYELOFIBROSIS OVER THE LAST 3 DECADES

EHA Library, Lucia Masarova, 324819